Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Revolving Door: Crawford Out, von Eschenbach In

This article was originally published in RPM Report

Executive Summary

National Cancer Institute director Andrew von Eschenbach has succeeded Lester Crawford as FDA commissioner. We spoke to three Wall streeters--two sell-side, one buy side--about what the succession means for investors.

You may also be interested in...



Avandia and the Commercial Impact of FDA's Credibility Gap

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

McClellan's FDA Team

When Mark McClellan became FDA commissioner in late 2002, he brought with him a cadre of like-minded managers and policy advisors. Many were economists; all were advocates for private-sector innovation. Most have departed from FDA. Their departures may have some short-term political benefits for the agency; but they leave a legacy of economic interest in the way FDA works and affects society.

Von Eschenbach to Stay at FDA

FDA Commissioner Andrew von Eschenbach is poised to remain head of the agency, either in an acting role or as the White House nominee, through the end of the second Bush term. Other candidates were interviewed-including drug safety expert Ray Woosley, MD, but the administration appears to be happy with the job the National Cancer Institute Director is doing.

Related Content

Topics

UsernamePublicRestriction

Register

PS079618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel